Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sensus Healthcare (SRTS)
NASDAQ:SRTS
SRTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.91 - $9.33
Previous CloseN/A
Volume208.66K
Average Volume (3M)444.47K
Market Cap
$95.72M
Enterprise Value$92.32M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)14.0
Beta1.73
Next Earnings
May 01, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding16,390,050
10 Day Avg. Volume814,673
30 Day Avg. Volume444,469
Standard Deviation0.21
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.32
Price to Cash Flow (P/CF)6.10
P/FCF Ratio6.60
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.57
Enterprise Value/Ebitda7.45
Forecast
1Y Price Target
$13.50Price Target Upside136.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Sensus Healthcare News
PremiumCompany Announcements
Sensus Healthcare Earnings Call Highlights Robust Growth
PremiumCompany Announcements
Sensus Healthcare Announces Strong 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Market DemandThe company shipped a record number of SRT systems in FY2024, exceeding expectations and showing strong market demand.
Revenue GrowthSensus Healthcare reported a 71% year-over-year revenue growth for FY2024, beating projections and supporting a Buy rating.
Strategic PartnershipsSensus is in discussions with 3-4 more private equity dermatology groups, signaling major growth opportunities.
Bears Say
Commercial Success RisksInvestment risks include potential failure of the SRT or TransDermal Infusion systems to achieve commercial success and potential dilution risk.
Revenue GuidanceGuidance indicates 1Q25 revenue to be considerably lower than 1Q24 revenue, mostly due to a difficult comparison and a shift toward the 'Fair Deal' model.
Sales ExpectationsManagement's commentary on sales expectations for the first quarter of 2025 being considerably lower than the previous year attracted negative attention.
---
Ownership Overview
11.46% Insiders
8.11% Mutual Funds
3.53% Other Institutional Investors
71.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRTS FAQ
What was Sensus Healthcare’s price range in the past 12 months?
Sensus Healthcare lowest stock price was $2.91 and its highest was $9.33 in the past 12 months.
What is Sensus Healthcare’s market cap?
Sensus Healthcare’s market cap is $95.72M.
When is Sensus Healthcare’s upcoming earnings report date?
Sensus Healthcare’s upcoming earnings report date is May 01, 2025 which is in 69 days.
How were Sensus Healthcare’s earnings last quarter?
Sensus Healthcare released its earnings results on Feb 05, 2025. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.124 by -$0.034.
Is Sensus Healthcare overvalued?
According to Wall Street analysts Sensus Healthcare’s price is currently Undervalued.
Does Sensus Healthcare pay dividends?
Sensus Healthcare does not currently pay dividends.
What is Sensus Healthcare’s EPS estimate?
Sensus Healthcare’s EPS estimate is 0.05.
How many shares outstanding does Sensus Healthcare have?
Sensus Healthcare has 16,390,050 shares outstanding.
What happened to Sensus Healthcare’s price movement after its last earnings report?
Sensus Healthcare reported an EPS of $0.09 in its last earnings report, missing expectations of $0.124. Following the earnings report the stock price went down -32.369%.
Which hedge fund is a major shareholder of Sensus Healthcare?
Among the largest hedge funds holding Sensus Healthcare’s share is Sheaff Brock Investment Advisors LLC. It holds Sensus Healthcare’s shares valued at 0.
---
Sensus Healthcare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (136.43% Upside)
$13.50 (136.43% Upside)
Blogger Sentiment
Bullish
SRTS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 40.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $8.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 24.8%
Last 30 Days ▲ 24.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.23%
12-Months-Change
Fundamentals
Return on Equity
12.70%
Trailing 12-Months
Asset Growth
15.71%
Trailing 12-Months
Company Description
Sensus Healthcare
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
---
SRTS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Sensus Healthcare, highlighted by strong revenue growth and profitability, successful product sales, and strategic initiatives like the Fair Deal Agreement program. However, challenges such as decreased gross profit margins and increased operating expenses were noted. The company's expansion into international markets and new sectors like veterinary medicine are promising, although seasonality may impact near-term sales.Read More>---
SRTS Stock 12 Month Forecast
Average Price Target
$13.50
▲(136.43% Upside)
Technical Analysis
Best Analysts Covering SRTS
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+47.98%
reiterated a buy rating 15 days ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +47.98% per trade.
---